drugset

drugset / Trial / NCT00545740

Prevention of Recurrence of Diverticulitis

NCT00545740 ↗

Phase 3 Completed 590 enrolled Shire

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine whether SPD476 is effective in reducing recurrence of diverticulitis.

Timeline

Start: 2007-11-28
Primary completion: 2012-03-05
Completion: 2012-03-05

Publications

Raskin JB, Kamm MA, Jamal MM, Marquez J, Melzer E, Schoen RE, Szaloki T, Barrett K, Streck P. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology. 2014 Oct;147(4):793-802. doi: 10.1053/j.gastro.2014.07.004. Epub 2014 Jul 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mesalamine	Small molecule	1.2 g	Oral
Subject	Mesalamine	Small molecule	2.4 g	Oral
Subject	Mesalamine	Small molecule	4.8 g	Oral

Indications